In current study, based on observation that high expression of CS in malignant ovarian tumors and ovarian cancer cell lines, we hypothesized that CS might contribute to the ovarian cancer phenotype as well as drug resistance and thus represent a therapeutic target. This evidence concerns the gene CS and ovarian cancer.